Q-omics provides the consensus-scored PPDPFL profile across patient tissues and cancer cell-line models. PPDPFL expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, PPDPFL is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, PPDPFL RNA expression shows 6,214 significant pathway-activity associations, with the highest sampling consensus in SARC. Together, these results highlight KICH, KIRC, and SARC as cancer lineages where PPDPFL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PPDPFL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PPDPFL survival associations across molecular data types. PPDPFL RNA expression shows survival associations in the most cancer types (19), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PPDPFL RNA expression–survival associations across cancer types. High PPDPFL expression shows unfavorable associations in KICH, HNSC, LIHC, UCEC, STAD and THCA. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KICH as the clearest survival context for PPDPFL RNA expression.
This table summarizes PPDPFL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PPDPFL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PPDPFL shows lower tumor expression in HNSC, BRCA, KICH, COAD and BLCA and higher tumor expression in KIRC. The KIRC box plot shows higher PPDPFL RNA expression in tumor versus normal tissue (log2 FC = +2.252, t-test p < 0.001).
This table shows molecular features associated with PPDPFL in patient tissues and cancer cell lines. In patient samples, PPDPFL shows the broadest associations at the RNA and protein expression levels, with SARC recurring as the lineage with the largest associated feature set. In cancer cell lines, PPDPFL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia.
